<DOC>
	<DOCNO>NCT01066195</DOCNO>
	<brief_summary>Pemetrexed know effective pulmonary adenocarcinoma gefitinib know effective non-small cell lung cancer ( NSCLC ) patient clinical characteristic adenocarcinoma , never smoker female . The investigator try evaluate drug ( pemetrexed v gefitinib ) efficious NSCLC patient clinical characteristic adenocarcinoma never smoke history second- further-line therapy .</brief_summary>
	<brief_title>Pemetrexed ( ALIMTA ) Gefitinib ( IRESSA® ) Never-Smoker Adenocarcinoma Patients With Non-Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>1 . Histologically confirm pulmonary adenocarcinoma include bronchioloalveolar , except adenosquamous cell carcinoma 2 . Stage IIIB ( malignant pleural effusion and/or pleural seeding ) , stage IV relapse nonsmall cell lung cancer 3 . Failed 1st line platinumbased chemotherapy relapse within 12 month adjuvant platinumbased chemotherapy ) 4 . Never smoker ( le 100 cigarette life time ) 5 . 18 year old 6 . ECOG 02 7 . No history biologic immunotherapy 8 . Tolerable renal function ( creatine clearance rate 60ml/min ) 9 . Tolerable hepatic function ( Serum bilirubin ≤ 1.25 x UNL , AST ( SGOT ) ALT ( SGPT ) ≤ 2.5 x UNL , alkaline phosphatase ≤5 x UNL ) 1. symptomatic brain metastasis 2. previously treat EGFR tyrosine kinase inhibitor 3. previously treat antifolate agent 4. poor oral absorption 5. patient active infection 6. uncontrolled diabetes mellitus 7. significant cardiovascular disease ( uncontrolled hypertension , history myocardial infarction unstable angina within 6 month , congestive heart failure ) 8. pregnant nursing patient 9. history malignant disease within 3 year enrollment except cure nonmelanomatous skin cancer , cervical carcinoma situ , thyroid carcinoma</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2010</verification_date>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>Never-Smoker Adenocarcinoma patient</keyword>
	<keyword>Pemetrexed ( ALIMTA )</keyword>
	<keyword>Gefitinib ( IRESSA® )</keyword>
</DOC>